NCCN Guidelines Insights: Bladder Cancer, Version 5.2018

J Natl Compr Canc Netw. 2018 Sep;16(9):1041-1053. doi: 10.6004/jnccn.2018.0072.

Abstract

The NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer. These NCCN Guidelines Insights discuss important updates to the 2018 version of the guidelines, including implications of the 8th edition of the AJCC Cancer Staging Manual on treatment of muscle-invasive bladder cancer and incorporating newly approved immune checkpoint inhibitor therapies into treatment options for patients with locally advanced or metastatic disease.

Publication types

  • Practice Guideline
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Intravesical
  • Aftercare / methods
  • Aftercare / standards
  • BCG Vaccine / therapeutic use
  • Chemotherapy, Adjuvant / adverse effects
  • Chemotherapy, Adjuvant / methods
  • Chemotherapy, Adjuvant / standards
  • Cystectomy / adverse effects
  • Cystectomy / methods
  • Cystectomy / standards
  • Humans
  • Lymphatic Metastasis / diagnosis
  • Lymphatic Metastasis / pathology
  • Medical Oncology / methods
  • Medical Oncology / standards*
  • Neoadjuvant Therapy / adverse effects
  • Neoadjuvant Therapy / methods
  • Neoadjuvant Therapy / standards
  • Neoplasm Staging
  • Organ Sparing Treatments / adverse effects
  • Organ Sparing Treatments / methods
  • Organ Sparing Treatments / standards
  • Patient Selection
  • Quality of Life
  • Radiotherapy, Adjuvant / adverse effects
  • Radiotherapy, Adjuvant / methods
  • Radiotherapy, Adjuvant / standards
  • Randomized Controlled Trials as Topic
  • Societies, Medical / standards
  • Treatment Outcome
  • United States
  • Urinary Bladder Neoplasms / diagnosis
  • Urinary Bladder Neoplasms / mortality
  • Urinary Bladder Neoplasms / pathology
  • Urinary Bladder Neoplasms / therapy*

Substances

  • BCG Vaccine